Skip Navigation LinksHome > April 2014 - Volume 21 - Issue 2 > The structure/function of apoprotein A-I mimetic peptides: a...
Current Opinion in Endocrinology, Diabetes & Obesity:
doi: 10.1097/MED.0000000000000045
LIPIDS: Edited by Annabelle Rodriguez

The structure/function of apoprotein A-I mimetic peptides: an update

Getz, Godfrey S.; Reardon, Catherine A.

Collapse Box

Abstract

Purpose of review

To review recent advances in our understanding of the mechanism of action of apoprotein A-I (apoA-I) mimetic peptides and improved methods for the oral delivery of peptides.

Recent findings

The apoA-I mimetic peptides are based on the structure of the major apoprotein of HDL with the expectation that they may also mimic some of the antiatherogenic functions of HDL. Recent work has provided insight into mechanisms by which they may be antioxidative and anti-inflammatory. In addition, recent work has shifted the focus of the site of action of the mimetic peptides to the small intestine from the plasma and HDL and suggests modulation of bioactive oxidized lipids in the intestine by the peptides may be a major antiatherogenic pathway. The development of transgenic tomatoes expressing an apoA-I mimetic peptide is a significant advance in the oral delivery of peptides as therapies for cardiovascular disease and other chronic inflammatory disorders.

Summary

In the past year, there have been important advances in the field of apoA-I mimetic peptides, including the oral delivery of bioactive peptides. Further work is required to fully understand the molecular basis for the effect of the peptide on the intestine and bioactive oxidized lipids.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.